A lack of standardized procedures may explain the observed variation in expression of KIT, and while its actual prevalence (and the clinical relevance of its presence in individual breast carcinomas) remains to be determined, it has been suggested that KIT, as part of a broader array of markers, could assist in the appropriate classification of breast cancer patients, and their subsequent assignment to therapy [14]. This evidence concerns the gene KIT and breast cancer.